ASCO oncology conference: NewLink Genetics (NLNK) -6.3% despite patients enjoying improved survival rates in a Phase II trial of the company's algenpantucel-L treatment for pancreatic cancer. NewLink Genetics has also disclosed positive results in early stage trials of two other drugs (I, II).
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at CNBC.com (Jan 6, 2015)
at Nasdaq.com (Jan 5, 2015)
at Benzinga.com (Dec 24, 2014)
at CNBC.com (Dec 24, 2014)
at Benzinga.com (Dec 22, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs